CareDx, Inc.
Close on Oct 19, 2026
- Market cap
- $3.58B
- P/E (TTM)
- 32.4
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | After market close | $132.00M | $2.07 | $0.37 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 16, 2026 | Before market open | $118.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | $108.00M | $-0.08 | $0.12 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $100.10M | $0.03 | $0.28 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $86.70M | $-0.16 | $0.10 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | After market close | $84.70M | $-0.19 | $0.09 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 15, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted EBITDAnon-GAAP | full year 2026 | $66.00M to $78.00M | New |
| revenue | full year 2026 | $490.00M to $500.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements CareDx filed with the SEC
CareDx Announces Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
CareDx Announces First Quarter 2026 Financial
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Apr 15, 2026 4:30 PM Eastern Daylight Time
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CareDx Announces Preliminary Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Derivatively on Behalf of CareDx, Inc.,
Other events · EX-99.1 to Form 8-K
THE ROSEN LAW FIRM, P.A.
Other events · EX-99.2 to Form 8-K
CareDx Announces Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Announces Second Quarter 2025 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Announces Repurchase of 5% of Outstanding Shares
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CareDx Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Transplant Solutions CompanyJ A N U A R Y 1 3 , 2 0 2 5 Patrick G, Kidney Transplant Recipient
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
CareDx Reports Preliminary Financial Results for Third Quarter 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
contained in this presentation, including statements regarding the future financial position of CareDx®, Inc. (together with its subsidiaries, “CareDx” or the “Company”), including financial targets and expectations,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Final Press Release For Newswire
Executive or director change · Other events · EX-99.1 to Form 8-K
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Patrick G, Kidney Transplant Recipient July 31, 2024 Q2 2024 Financial and Business Presentation
Results of operations · EX-99.2 to Form 8-K
CareDx Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Patrick G, Kidney Transplant Recipient Q1 2024 Earnings Presentation May 9, 2024 The Transplant Company™
Results of operations · EX-99.2 to Form 8-K
John W. Hanna as its New President and Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
CareDx Appoints Bryan Riggsbee to Its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
across the entire transplant patient journey Corporate Presentation January 9, 2024 Patrick G. Kidney Transplant Recipient
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
CareDx Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Board Establishes Office of the CEO, Conducts Search for Successor
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CareDx Reports Second Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
CareDx Reports First Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
CareDx Reports Fourth Quarter and Full Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
Leslie M, Kidney Transplant Recipient Focused on improving care across the entire transplant patient journey The Transplant Company™ Earnings Presentation Q4 and FY 2022
Results of operations · EX-99.2 to Form 8-K
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Focused on improving care across the
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BRISBANE, Calif.—(BUSINESS WIRE) – CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its
Regulation FD disclosure · EX-99.1 to Form 8-K